Dr. Ron Elfenbein, an emergency physician in Maryland, is speaking out about his experience treating COVID-19 patients with monoclonal antibodies and fighting the Biden administration over the treatment. In an interview reported by The Gateway Pundit, Elfenbein described the therapy as a powerful option that was pushed aside after the government ended its authorization and distribution. He warned at the time, “People are definitely going to die.”
Elfenbein later faced a five-count, $15 million health care fraud case brought by the Biden Department of Justice in 2022. A jury convicted him, but District Judge James K. Bredar later acquitted him, writing that “the evidence weighs so heavily against the verdict.” That ruling did not end the matter. A federal appeals court overturned the acquittal earlier this year and sent the case back to the District Court for a new trial.
A source in the Trump Administration told The Gateway Pundit that Elfenbein had been “subject to a tremendous injustice” and expressed hope that “things can be made right” under President Trump. The doctor’s account presents the case as more than a courtroom dispute. He argues that the treatment was effectively pushed out of the way while a patented pill became a more lucrative option for the Biden administration and “big pharma.” Washington has never been known for making health policy simple, but this story adds an especially expensive layer of bureaucracy and controversy.
Elfenbein said his interest in monoclonal antibodies began after President Trump received REGN-COV2 during his COVID-19 illness in October 2020. Watching President Trump recover, Elfenbein said he immediately saw the treatment as something that should be made broadly available. He recalled President Trump saying, “Man, I feel like a new person. They gave me monoclonal antibodies.”
“This is what we should be talking about. Right there is the cure for COVID. We have it in our hands. We got to be embracing this,” Elfenbein said. He petitioned Maryland for permission to operate a monoclonal antibody infusion center and said the facility quickly became the largest supplier of the treatment in Maryland and, to his knowledge, across the eastern seaboard outside Florida.
Elfenbein described monoclonal antibody technology, which he said had been studied since the 1970s, as a “tried and true method of getting people better.” The treatment received emergency authorization, but he said it was never approved for hospital use in the United States. During an August 2021 White House press briefing, Anthony Fauci called monoclonal antibodies “a much-underutilized intervention” and said they could “reduce the risk of COVID-19 hospitalization or death by 70 to 85 percent.”
Explaining the treatment, Elfenbein compared it to “a supercharged immune system.” Instead of waiting for the body to produce antibodies, the treatment delivered them directly, potentially providing protection for several months, according to his description. His broader complaint is that Americans were promised access to a treatment described as a cure during President Trump’s first term, only to see it used temporarily and then discarded under the Biden administration. The dispute now sits alongside his pending legal case, a policy fight, and serious accusations about who benefited when the treatment disappeared.
Leave a Comment